A gapmer antisense oligonucleotide targeting SRRM4 is a novel therapeutic medicine for lung cancer

Small cell lung cancer (SCLC) is the most aggressive neuroendocrine phenotype of the deadliest human lung cancers. However the therapeutic landscape for SCLC has not changed in over 30 years. Effective treatment and prognosis are needed to combat this aggressive cancer. Herein we report that Ser/Arg...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Scientific reports 2019-05, Vol.9 (1), p.7618, Article 7618
Hauptverfasser:	Shimojo, Masahito, Kasahara, Yuuya, Inoue, Masaki, Tsunoda, Shin-ichi, Shudo, Yoshie, Kurata, Takayasu, Obika, Satoshi
Format:	Artikel
Sprache:	eng
Schlagworte:	13/109 13/2 38/77 38/90 59/5 631/67/1059/153 64/60 692/4028/67/1612/2143 A549 Cells Animals Antisense oligonucleotides Cell death Cell Line, Tumor Exosomes Gene Expression Regulation, Neoplastic - drug effects Humanities and Social Sciences Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - metabolism Lung Neoplasms - pathology Male MCF-7 Cells Mice Mice, Inbred BALB C Mice, Nude MicroRNAs - metabolism miRNA mRNA multidisciplinary Nerve Tissue Proteins - metabolism Nucleotides Oligonucleotides, Antisense - pharmacology Phenotypes Prognosis RNA, Messenger - metabolism Science Science (multidisciplinary) Small cell lung carcinoma Small Cell Lung Carcinoma - drug therapy Small Cell Lung Carcinoma - metabolism Small Cell Lung Carcinoma - pathology Splicing Therapeutic applications Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!